Body Location or Region – Page 2

Merus’s Petosemtamab Demonstrates Promising Efficacy in Expanded HNSCC Dataset

11 months ago talkbio0Tagged Clinical Trials, Congress (U.S. Legislature), ESMO, Head, Malignant Neoplasms, Merus, MRUS, N.V., Petosemtamab, Squamous cell carcinoma of the head and neck

Petosemtamab, HNSCC (Head and Neck Squamous Cell Carcinoma), Merus N.V. (MRUS), Clinical Trial Results, Cancer Treatment, ESMO Asia Congress 2024

Sinaptica’s Neuromodulation Therapy Demonstrates 44% Reduction in Alzheimer’s Disease Progression

12 months ago talkbio0Tagged Alzheimer 's disease, Default Mode Network, Disease Progression, neuromodulation therapy, Non-invasive therapy, Personalized Treatment, Sinaptica, Stimulation procedure, Structure of precuneus

Sinaptica Therapeutics, Neuromodulation therapy, Alzheimer’s disease, Disease progression reduction, Personalized treatment, Non-invasive therapy, Default Mode Network (DMN), Precuneus stimulation

HLTH24: Atropos Health Introduces AI-Powered Chat Co-Pilot for Rapid Real-World Evidence Generation

1 year ago talkbio0Tagged Atropos, Chat-Based AI, ChatRWD, Evidence, Generative AI, GENEVA, Health, Health care facility, HLTH24, Oral region, Pilot, Real-world

Atropos Health, HLTH24, Chat-Based AI Co-Pilot, Real-World Evidence, Generative AI, Healthcare Evidence Generation, GENEVA OS, ChatRWD

IO Biotech’s IO102-IO103 Vaccine in Combination with Keytruda Shows Promising Results in Phase 2 Trial for Advanced Squamous Cell Carcinoma of the Head and Neck

1 year ago talkbio0Tagged biotech, Cancer Vaccines, Head and neck structure, Immunotherapy, Io satellite, IO102-IO103, Keytruda, pembrolizumab, Phase 2 trial, Squamous cell carcinoma, Squamous cell carcinoma of the head and neck

IO Biotech, IO102-IO103, Keytruda (pembrolizumab), Phase 2 trial, Squamous cell carcinoma of the head and neck (SCCHN), Cancer vaccine, Immunotherapy

OS Therapies Refiles IPO for $6M to Fund Phase 2 HER2 Drug and Preclinical ADCs

1 year ago talkbio0Tagged ADCs, American exchange, HER2 drug, Immunotherapy, IPO, Oral region, Preclinical

OS Therapies, IPO, HER2 drug, preclinical ADCs, immunotherapy, NYSE American exchange

BioMarin’s Brineura Receives Significant Label Expansion from FDA for Children Under 3 with CLN2 Disease

1 year ago talkbio0Tagged Alfa, BioMarin, Brineura, cerliponase, Child, Deterioration, expansion, Injection of therapeutic agent, Intraventricular, Labels (device), motor ability, Neurodegenerative, Symptoms aspect, TPP1 gene, United States Food and Drug Administration

BioMarin, Brineura, FDA, Label Expansion, CLN2 Disease, Children Under 3, Cerliponase Alfa, Intraventricular Injection, Motor Ability Deterioration, Neurodegenerative Symptoms